Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

Next Previous
Search
Trial Profile

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dersimelagon (Primary)
  • Indications Erythropoietic protoporphyria
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ENDEAVOR
  • Sponsors Mitsubishi Tanabe Pharma America

    • Most Recent Events

    • 13 Apr 2023 Results published in the New England Journal of Medicine
    • 08 Dec 2020 Results post-hoc subgroup analysis assessing effects of baseline ePPIX levels in subjects categorized based on baseline median ePPIX level of 1981 µg/dL presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
    • 15 Jun 2020 According to a Mitsubishi Tanabe Pharma Corporation media release, results from this trial were presented in the late-breaking clinical session at the annual AAD 2020 conference

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top